| Please  | type | а | plus | sian | <b>(+</b> ) | inside | this | hox | 4             |
|---------|------|---|------|------|-------------|--------|------|-----|---------------|
| i icasc | type | а | pius | Sign | 1.1         | moluc  | เมเจ | NOX | $\Rightarrow$ |

E-2-5,

| Please type a plu  | is sign (+) inside this box 🖾       | 10.  |  |  |  |                              |  |
|--|-------------------------------------|--|--|--|--|------------------------------|--|
| UTILITY  |                                     | Attorney Docket No.  |  | ORT-1517   |  |                              |  |
| PATENT A   | First Inventor                      | KORDIK ET AL.  |  |  | - OL   |                              |  |
| TRAN   | Title                               |  | NOVEL AMIDOALKYL-PIPERIDINE AND AMIDOA<br>PIPERAZINE DERIVATIVES USEFUL FOR THE<br>TREATMENT OF NERVOUS SYSTEM DISORDER  |  | <i>ω</i> — .   |                              |  |
| C (only for new nonprovisional applications under 37 CFR (only for |                                     |  |  |  |  |                              |  |
|  | ON ELEMENTS                         |  | ADD  | RESS TO:   | Commissioner for Patents   | 5<br>6-1                     |  |
| ee MPEP Chapter 600 contents.  | o concerning utility patent app     | lication   | Box Patent Application<br>Washington, DC 20231   |  |  |                              |  |
| <ol> <li>Fee Transmittal Form (e.g., PTO/SB/17)         (submit an original and a duplicate for fee processing)</li> <li>Applicant claims small entity status.</li> <li>Specification [Total Pages 125]         (Preferred arrangement set forth below)         - Descriptive Title of the Invention         - Cross Reference to Related Applications         - Statement Regarding Fed sponsored R&amp;D         - Reference to sequence listing, a table, or a computer program listing appendix         - Brief Summary of the Invention         - Brief Description of the Drawings (if filed)         - Detailed Description         - Claim(s)         - Abstract of the Disclosure</li> <li>Tod-ROM or CD-R in duplicate Computer Program (Appendix)         - Submission (if applicable, all not all program (CRF)         - Submission (if applicable, all not all program (CRF)         - Submission (if applicable, all not all program (CRF)         - Submission (if applicable, all not all program (CRF)         - Submission (if applicable, all not all program (CRF)         - Submission (if applicable, all not all program (CRF)         - Submission (if applicable, all not all program (CRF)         - Submission (if applicable, all not all program (CRF)         - Submission (if applicable, all not all program (CRF)         - Submission (if applicable, all not all program (CRF)         - Submission (if applicable, all not all program (CRF)         - Detailed Description         - Brief Summary of the Invention         - Brief Summary of the Invention         - Brief Description of the Drawings (if filed)         - Detailed Description         - Claim(s)         - Claim(s)         - Abstract of the Disclosure         - In program (Appendix)         - Submission (if applicable, all not all program (CRF)         - CRD-ROM or CD-R (2 copies ii. □ paper could program (CRF)         - Detailed Description of the Drawings (if filed)         - Detailed Description of the Drawings (if filed)         - Detailed Description of the Drawings (if fil</li></ol>    |                                     |  |  |  | CD-R in duplicate, large to m (Appendix)  For Amino Acid Sequence frapplicable, all necessary) dable Form (CRF) equence Listing on: or CD-R (2 copies); or sying identity of above copies of the copie | e <b>TS</b> s)) attorney de) |  |
| 18. ☐ If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:   |                                     |  |  |  |  |                              |  |
| Continuation Frior application info<br>For CONTINUATION oath or declaration is continuation or divis   | Divisional                          | ation-in-Part (Cl<br>Group of<br>Gonly: The enti<br>Gonis considered<br>hereby incorporatently omitted | IP) of part Un ire disconnection of the image in the imag | orior application<br>it:<br>closure of the p<br>of the disclosu<br>y reference. T<br>ne submitted ap | rior application, from which a<br>rre of the accompanying<br>he incorporation can only be  |                              |  |
| 19. CORRESPONDENCE ADDRESS  ☑ Customer Number or Bar Code Label 000027777 or ☐ Correspondence Address below  |                                     |  |  |  |  |                              |  |
| Name: Philip S. Johnson, Esq.  |                                     |  |  |  |  |                              |  |
|  | nson & Johnson<br>Johnson & Johnson | Plaza  |  |  |  |                              |  |
|  | v Brunswick, NJ 0893                |  | Д  |  |  |                              |  |
| 20. TELEPHONE CONTACT  |                                     |  |  |  |  |                              |  |
| Telephone: (73   |                                     | ax: (732) 524  | 4-2808   | 3  |  |                              |  |
| 21. S  | IGNATURE OF APPL                    | ICANT, ATTO  | ORNE   | Y, OR AGEN   | T REQUIRED   |                              |  |
| NAME   | Mary A. Appollina                   |  | —  |  | Reg. No. 34087   |                              |  |
| SIGNATURE  | Mary a. az                          | pollera  |  |  |  |                              |  |
| DATE   | October 22, 2001                    |  |  |  |  |                              |  |

# The state of the s

## Complete if Known Application Number Filing Date First Named Inventor KORDIK et al. Group Art Unit Examiner Name Attorney Docket Number ORT-1517

### **FEE CALCULATION**

**FEE TRANSMITTAL** 

### **CLAIMS AS FILED**

| (1)                             | (2)          | (3)             | (4)       | (5)                   |
|---------------------------------|--------------|-----------------|-----------|-----------------------|
| FOR:                            | NUMBER FILED | NUMBER<br>EXTRA | RATE      | BASIC FEE<br>\$710.00 |
| TOTAL CLAIMS                    | 18 - 20 =    | 0               | x 18.00   | \$ 0.00               |
| INDEPENDENT<br>CLAIMS           | 1 - 3 =      | 0               | x 80.00   | \$ 0.00               |
| MULTIPLE<br>DEPENDENT<br>CLAIMS |              | N/A             | \$270.00  |                       |
|                                 |              | TOTAL FEES      | \$ 710.00 |                       |

### **METHOD OF PAYMENT**

- Please charge Deposit Account No. 10-0750/ORT1517/MAA in the amount of \$710.00. Three copies of this sheet are enclosed.
- The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the filing of this communication, or credit any overpayment, to Account No. 10-0750/ORT1517/MAA. Three copies of this sheet are enclosed.

| SUBMITTED B  | Complete (if applicable) |                 |                                |
|--------------|--------------------------|-----------------|--------------------------------|
| Typed or     |                          |                 |                                |
| Printed Name | Mary A. Appollina        |                 | Reg. No. 34087                 |
| Signature    | Mary a Ogolhua           | Date: 10/22/011 | Deposit Account<br>No. 10-0750 |

DOCKET NO. ORT-1517

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: KORDIK ET AL.

For : NOVEL

OVEL AMIDOALKYL-PIPERIDINE AND AMIDOALKYL-

PIPERAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF

NERVOUS SYSTEM DISORDERS

## Express Mail Certificate

"Express Mail" mailing number: EF195557749US

Date of Deposit:

October 22, 2001

I hereby certify that this complete application, including specification pages, claims, Declaration and Power of Attorney, and Assignment, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

KAREN HALL-MORGAN

(Typed or printed name of Joing) mailing paper or fee)

(Signature of person mailing paper or fee)